
AMALGAM RX EU LIMITED
727036
Unaudited Financial Statements
December 31, 2025

Contents	Page
Names of Directors and other information	1
Balance Sheet	2
Profit and Loss Account	3
Directors Compliance Statement	4
Notes to the Financial Statements	5

Names of Directors and Other Information

Company Registration Number:	727036
Place of Registration:	Ireland
Legal Form of Company:	Limited
Registered Office:	70 Sir John Rogerson's Quay, Dublin 2, Dublin, DO2 R296, Ireland
Directors:	Ryan A. Sysko
Secretary:	Matsack Trust Limited

AMALGAM RX EU LIMITED
BALANCE SHEET as at December 31, 2025

Current Year
2025

Called up share capital not paid	-
Fixed Assets	-
Current Assets	-
Prepayment and accrued income	-
Creditors: amounts falling due within one year	-
Provisions for liabilities	-
Accruals and deferred income	-
Capital and reserves	-

We the directors of Amalgam Rx EU Limited state that;


(a) the company is availing itself of the exemption provided for by Chapter 16 of Part 6 of the Companies Act 2014;

(b) the company is availing itself of the exemption on the grounds that the conditions specified in s.365(2) are satisfied;

(c) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare Financial Statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of the Companies Act 2014 relating to Financial Statements so far as they are applicable to the company

(d) we hereby certify that we have relied on the specific exemption contained in s.365 Companies Act 2014 on the grounds that the company is entitled to the benefits of that exemption as a dormant company

On behalf of the board



Ryan A. Sysko

Director

March 11, 2026

AMALGAM RX EU LIMITED
Profit & Loss Account for the year ended December 31, 2025


	<u>For the Year Ended December 31, 2025</u>
Turnover	-
Cost of Sales	-
Gross Profit	<u>-</u>
Profit for the Financial Year	<u><u>-</u></u>

AMALGAM RX EU LIMITED
Directors Compliance Statement

As required by Section 225 of the Companies Act 2014, the directors acknowledge they are responsible for securing compliance by the Company with its Relevant Obligations as defined in the Companies Act 2014 (hereinafter called the Relevant Obligations).

The directors confirm the Company (i) has drawn up and adopted a compliance policy statement setting out the Company's policies that, in the directors' opinion, are appropriate to the Company respecting compliance by the Company with its Relevant Obligations; and (ii) has put in place appropriate arrangements or structures that are, in the directors' opinion, designed to secure material compliance with the Company's Relevant Obligations.

A review of the arrangements and structures in place to ensure compliance with the Company's Relevant Obligations has been conducted in the financial year to which this report relates.



Ryan A. Sysko
Director
March 11, 2026

AMALGAM RX EU LIMITED
Notes to the Company Financial Statements

1. Basis of Presentation and Summary of Significant Accounting Policies

Amalgam RX EU Limited (the Company), headquartered in Ireland, is a healthcare technology importer. The Company is incorporated as a company limited by shares in the Republic of Ireland (registration number 727036). The address of its registered office is 70 Sir John Rogerson's Quay, Dublin 2, Dublin, D02 R296, Ireland.

Significant Accounting Policies

The significant accounting policies used in the preparation of the entity financial statements are set out below. These policies have been consistently applied to all financial years presented.

Basis of Preparation

The entity financial statements have been prepared under the historical cost convention. The preparation of financial statements in conformity with FRS 102 requires the use of certain key assumptions concerning the future, and other key sources of estimation uncertainty at the reporting date. It also requires the directors to exercise their judgment in the process of applying the Company's accounting policies. Estimates and judgments made in the process of preparing the entity financial statements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical Accounting Estimates

The directors make estimates and assumptions concerning the future in the process of preparing the entity financial statements. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year primarily relate to the carrying value of the investment in subsidiary undertakings.